Clinical Trial Update: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the highest dose of uproleselan in combination with fludarabine and cytarabine for relapsed or refractory acute myeloid leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Fludarabine (Fludarabine)
• Uproleselan (uproleselan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy | Phase 1 | Status: ACTIVE_NOT_RECRUITING